Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IPI Legacy Liquidation Co IMPLQ

Healthcare Biotechnology
IPI Legacy Liquidation Co, formerly Impel Pharmaceuticals Inc., is not engaged in any business operations. The Company doesn’t hold any assets.

Recent & Breaking News (PINL:IMPLQ)

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

GlobeNewswire July 19, 2022

Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society

GlobeNewswire June 9, 2022

Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

GlobeNewswire June 8, 2022

Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2022

Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

GlobeNewswire May 12, 2022

Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

GlobeNewswire May 9, 2022

Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation

GlobeNewswire April 25, 2022

Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25

GlobeNewswire April 21, 2022

Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference

GlobeNewswire April 7, 2022

Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 24, 2022

Impel NeuroPharma to Present Trudhesa(TM) Data at 2022 Scientific Meeting of American Academy of Neurology

GlobeNewswire March 22, 2022

Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

GlobeNewswire March 17, 2022

Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree

GlobeNewswire March 17, 2022

Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire February 28, 2022

Impel NeuroPharma Provides Updates on Trudhesa(TM) Launch and Recent Business Highlights

GlobeNewswire January 18, 2022

Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 15, 2021

Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference

GlobeNewswire November 9, 2021

Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

GlobeNewswire November 8, 2021

Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa(TM) (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

PR Newswire September 29, 2021

Carepoint Pharmacy Selected by Impel NeuroPharma as a Digital Pharmacy Partner for the Launch of Trudhesa(TM) (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine

PR Newswire September 28, 2021